SwanBio, based on research at Harvard Medical School, has secured a $20m extension to bring its series A round to $45m so far, with commitments to increase it to $77m.

Forest Partners and Activant Capital have invested $11m in the SoftBank-backed agriculture trading hub.

M Ventures and Novartis Venture Fund co-led a round for the oncology drug startup that also featured fellow corporate venturing unit Pfizer Ventures.

Novartis DRX was among the investors in a $12.9m for the medical personnel database operator that lifted its overall funding close to $20m.

Dumac contributed to a round that took the total raised by the cancer screening system developer past the $130m mark.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

EPFL spinout Lunaphore has received $2m in a series C extension provided by Swiss Entrepreneurs Fund, adding to an initial $23.6m tranche led by PHC Holdings three months ago.

Guru has closed a $30m series C round backed by returning investor Slack, bringing the sales advice software developer’s total funding to $68m.

Satt AxLR-allied Phost'in Therapeutics has secured funding to progress cancer drugs targeting glycosylation and the body's immune system.

Lunaphore has received $2m in a series C extension provided by Swiss Entrepreneurs Fund, adding to an initial $23.6m tranche led by PHC Holdings three months ago.